The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Systematic identification of genomic markers of drug sensitivity in cancer cells
Open accessAbstract
Clinical responses to anticancer therapies are often restricted to a subset of patients. In some cases, mutated cancer genes are potent biomarkers for responses to targeted agents. Here, to uncover new biomarkers of sensitivity and resistance to cancer therapeutics, we screened a panel of several hundred cancer cell lines--which represent much of the tissue-type and genetic diversity of human cancers--with 130 drugs under clinical and preclinical investigation. In aggregate, we found that mutated cancer genes were associated with cellular response to most currently available cancer drugs. Classic oncogene addiction paradigms were modified by additional tissue-specific or expression biomarkers, and some frequently mutated genes were associated with sensitivity to a broad range of therapeutic agents. Unexpected relationships were revealed, including the marked sensitivity of Ewing's sarcoma cells harbouring the EWS (also known as EWSR1)-FLI1 gene translocation to poly(ADP-ribose) polymerase (PARP) inhibitors. By linking drug activity to the functional complexity of cancer genomes, systematic pharmacogenomic profiling in cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Large-scale efforts aimed at linking tumor genomic alterations with sensitivity to cytotoxic and targeted therapies have uncovered a wealth of pharmacogenomic interactions in NSCLC and other cancer types149–152.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [150]
In the citing paper
“BRAF mutation was associated with nutlin 3a sensitivity in the same study130.”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [130]
In the citing paper
“p53 mutation status was the strongest indicator of nutlin 3a resistance”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [130]
In the citing paper
“Even with such a simple readout, genes and pathways that determine drug response can be identified,199,200”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [199]
In the citing paper
“More than 1200 established cancer cell lines and newly derived organoid models comprise the foundational model set of the Passports, including all those utilized in the Sanger’s GDSC project (5, 18) as well as cell models generated as part of the Human Cancer Models Initiative.”
From Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citationBolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,328
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Clustering by Passing Messages Between Data Points
Frey, B. J., & Dueck, D. (2007) · Science · doi:10.1126/science.1136800 · Cited by 6,855
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Self-citationBoland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,004
Nieborowska-Skorska, M., Sullivan, K., Dasgupta, Y., Podszywalow‐Bartnicka, P., Hoser, G., Maifrede, S., Martı́nez, E., Marcantonio, D. D., Bolton-Gillespie, E., Cramer-Morales, K. L., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90825 · Cited by 74
canSAR: updated cancer research and drug discovery knowledgebase
Bulusu, K. C., Tym, J. E., Coker, E. A., Schierz, A. C., & Al‐Lazikani, B. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1182 · Cited by 74
Ferreira, D., Adega, F., & Chaves, R. (2013) · InTech eBooks · doi:10.5772/53110 · Cited by 79
Smith, M. A., Hampton, O. A., Reynolds, C. P., Kang, M. H., Maris, J. M., Gorlick, R. G., Kolb, E. A., Lock, R. B., Carol, H., Keir, S. T., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25201 · Cited by 74
VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer
Hart, S., Novotny‐Diermayr, V., Goh, K. C., Williams, M. R. V., Tan, Y. C., Ong, L. C., Cheong, A., Ng, B. K., Amalini, C., Madan, B., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0466 · Cited by 74
Self-citationHomoharringtonine (omacetaxine mepesuccinate) as an adjunct forFLT3-ITD acute myeloid leukemia
Lam, S. S. Y., Ho, E. S. K., He, A. B.-L., Wong, W.-W., Cher, C. Y., Ng, N. K. L., Man, C., Gill, H., Cheung, A. M. S., Ip, H., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf3735 · Cited by 74
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
Smith, M. P., Rowling, E. J., Miskolczi, Z., Ferguson, J., Spoerri, L., Haass, N. K., Sloss, O., McEntegart, S., Arozarena, I., von Kriegsheim, A., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607156 · Cited by 77
Peón, A., Naulaerts, S., & Ballester, P. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-04264-w · Cited by 76
Sambrooks, C. L., Baro, M., Quijano, A., Narayan, A., Cui, W., Greninger, P., Egan, R. K., Patel, A. A., Benes, C. H., Saltzman, W. M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0505 · Cited by 74
Self-citationLazzari, L., Corti, G., Picco, G., Isella, C., Montone, M., Arcella, P., Durinikova, E., Zanella, E. R., Novara, L., Barbosa, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3440 · Cited by 74
Self-citationSystematic discovery of mutation-directed neo-protein-protein interactions in cancer
Mo, X., Niu, Q., Ivanov, A. A., Tsang, Y. H., Tang, C., Shu, C., Li, Q., Qian, K., Wahafu, A., Doyle, S. P., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.014 · Cited by 73
Self-citationDietlein, F., Thelen, L., Jokić, M., Jachimowicz, R. D., Ivan, L., Knittel, G., Leeser, U., van Oers, J., Edelmann, W., Heukamp, L. C., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0907 · Cited by 70
Ammad-ud-din, M., Khan, S. A., Wennerberg, K., & Aittokallio, T. A. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx266 · Cited by 73
Heske, C. M., Davis, M. I., Baumgart, J. T., Wilson, K. M., Gormally, M. V., Chen, L., Zhang, X., Ceribelli, M., Duveau, D. Y., Guha, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1121 · Cited by 73
Self-citationCooperation of cancer drivers with regulatory germline variants shapes clinical outcomes
Musa, J., Cidre‐Aranaz, F., Aynaud, M.-M., Orth, M. F., Knott, M. M. L., Mirabeau, O., Mazor, G., Varon, M., Hölting, T. L. B., Grossetête, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12071-2 · Cited by 72
Self-citationA Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma
Johansson, P., Krona, C. C., Kundu, S., Doroszko, M., Baskaran, S., Schmidt, L., Vinel, C., Almstedt, E., Elgendy, R., Elfineh, L., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107897 · Cited by 70
Drugging the Undruggable: Advances on RAS Targeting in Cancer
Molina‐Arcas, M., Samani, A., & Downward, J. (2021) · Genes · doi:10.3390/genes12060899 · Cited by 76
Khan, M. B., Lin, J., Wang, B., Chen, C., Huang, Z., Tian, Y., Yuan, Y., & Bu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968165 · Cited by 72
Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth
Nakazawa, M. S., Eisinger‐Mathason, T. S. K., Sadri, N., Ochocki, J. D., Gade, T. P. F., Amin, R. K., & Simon, M. C. (2016) · Nature Communications · doi:10.1038/ncomms10539 · Cited by 72
Liu, H., Zhao, Y. F., Zhang, L., & Chen, X. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.09.011 · Cited by 72
Multilevel models Improve precision and Speed of IC 50 Estimates
Vis, D. J., Bombardelli, L., Lightfoot, H., Iorio, F., Garnett, M. J., & Wessels, L. F. (2016) · Pharmacogenomics · doi:10.2217/pgs.16.15 · Cited by 71
“This model outperform the Bayesian model used in Garnett et al.[3]*.”
BackgroundMethodInfluentialSelf-citationA chemical–genetic interaction map of small molecules using high‐throughput imaging in cancer cells
Breinig, M., Klein, F. A., Huber, W. K., & Boutros, M. (2015) · Molecular Systems Biology · doi:10.15252/msb.20156400 · Cited by 70
Gu, Z., Yao, Y., Yang, G., Zhu, G.-P., Tian, Z., Wang, R., Wu, Q., Wang, Y.-J., Wu, Y.-P., Chen, L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo5987 · Cited by 52
Self-citationPignochino, Y., Capozzi, F., D’Ambrosio, L., Dell’Aglio, C., Basiricò, M., Canta, M., Lorenzato, A., Lutati, F. V., Aliberti, S., Palesandro, E., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0652-5 · Cited by 72
Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells
Her, N.-G., Oh, J.-W., Oh, Y. J., Han, S., Cho, H. J., Lee, Y., Ryu, G. H., & Nam, D.-H. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0825-1 · Cited by 68
Calsina, B., Castro‐Vega, L. J., Torres‐Pérez, R., Inglada‐Pérez, L., Currás-Freixes, M., Roldán‐Romero, J. M., Mančíková, V., Letón, R., Remacha, L., Santos, M., et al. (2019) · Theranostics · doi:10.7150/thno.35458 · Cited by 70
Multifaceted regulation and functions of replication factor C family in human cancers.
Li, Y., Gan, S., Ren, L., Yuan, L., Liu, J., Wang, W., Wang, X., Zhang, Y., Jiang, J., Zhang, F., et al. (2018) · Europe PMC (PubMed Central) · Cited by 68
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Merz, V., Gaule, M., Zecchetto, C., Cavaliere, A., Casalino, S., Pesoni, C., Contarelli, S., Sabbadini, F., Bertolini, M., Mangiameli, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638360 · Cited by 74
the 11q13‐q14 amplicon: Clinicopathological correlations and potential drivers
Wilkerson, P. M., & Reis-Filho, J. S. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22037 · Cited by 70
A Transcriptional Program for Detecting TGFβ-Induced EMT in Cancer
Foroutan, M., Cursons, J., Hediyeh-zadeh, S., Thompson, E. W., & Davis, M. J. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0313 · Cited by 70
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia
Follini, E., Marchesini, M., & Roti, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123021 · Cited by 73
Szalai, B., Subramanian, V., Holland, C. H., Alföldi, R., Puskás, L. G., & Sáez-Rodríguez, J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz805 · Cited by 68
An overview of machine learning methods for monotherapy drug response prediction
Firoozbakht, F., Yousefi, B., & Schwikowski, B. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab408 · Cited by 70
The Role of the APC/C and Its Coactivators Cdh1 and Cdc20 in Cancer Development and Therapy
Greil, C., Engelhardt, M. M., & Wäsch, R. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.941565 · Cited by 71
Li, Y., Liu, Y., Yu, X., Xu, Y., Pan, X., Sun, Y. E., Wang, Y., Song, Y.-H., & Shen, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02013-w · Cited by 72
EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation
Wang, M., Kern, A. M., Hülskötter, M., Greninger, P., Singh, A., Pan, Y., Chowdhury, D., Krause, M., Baumann, M. A., Benes, C. H., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3157 · Cited by 70
Self-citationTransfer Learning Approaches to Improve Drug Sensitivity Prediction in Multiple Myeloma Patients
Turki, T., Wei, Z., & Wang, J. T. L. (2017) · IEEE Access · doi:10.1109/access.2017.2696523 · Cited by 69
Mahoney, C. E., Pirman, D. A., Chubukov, V., Sleger, T., Hayes, S., Fan, Z. P., Allen, E. L., Chen, Y., Huang, L., Liu, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07959-4 · Cited by 69
Liu, X., Yang, J., Zhang, Y., Fang, Y., Wang, F., Wang, J., Zheng, X., & Yang, J. (2016) · Scientific Reports · doi:10.1038/srep22811 · Cited by 63
He, L., Torres‐Lockhart, K., Forster, N., Ramakrishnan, S., Greninger, P., Garnett, M. J., McDermott, U., Rothenberg, S. M., Benes, C. H., & Ellisen, L. W. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0417 · Cited by 67
Self-citationLarge-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines
Zhao, W., Li, J., Chen, M.-J. M., Luo, Y., Ju, Z., Nesser, N. K., Johnson-Camacho, K., Boniface, C. T., Lawrence, Y., Pande, N. T., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.008 · Cited by 68
Gautam, P., Karhinen, L., Szwajda, A., Jha, S. K., Yadav, B., Aittokallio, T. A., & Wennerberg, K. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0517-3 · Cited by 66
Luo, T., David, M. A., Dunshee, L. C., Scott, R. A., Urello, M. A., Price, C., & Kiick, K. L. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b00686 · Cited by 68
Kernelized rank learning for personalized drug recommendation
He, X., Folkman, L., & Borgwardt, K. M. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty132 · Cited by 67
DeSigN: connecting gene expression with therapeutics for drug repurposing and development
Lee, B. K. B., Tiong, K. H., Chang, J. K., Liew, C. S., Rahman, Z. A. A., Tan, A. C., Khang, T. F., & Cheong, S. C. (2017) · BMC Genomics · doi:10.1186/s12864-016-3260-7 · Cited by 66
Self-citationApplicability of drug response metrics for cancer studies using biomaterials
Brooks, E. A., Galarza, S., Gencoglu, M. F., Cornelison, R. C., Munson, J. M., & Peyton, S. R. (2019) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2018.0226 · Cited by 70
Johnson, J., Bergman, D. R., da Rocha, H. L., Zhou, D. L., Cramer, E. M., McLean, I. C., Dance, Y. W., Booth, M. I., Nicholas, Z., Lopez-Vidal, T. Y., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.048 · Cited by 82
EGF-Induced Centrosome Separation Promotes Mitotic Progression and Cell Survival
Mardin, B. R., Isokane, M., Cosenza, M. R., Krämer, A., Ellenberg, J., Fry, A. M., & Schiebel, E. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.03.012 · Cited by 67
GLUT1 and GLUT3 involvement in anthocyanin gastric transport- Nanobased targeted approach
Oliveira, H., Roma‐Rodrigues, C., Santos, A. I., Veigas, B., Brás, N. F., Faria, A., Calhau, C., de Freitas, V. A. P., Baptista, P. V., Mateus, N. F. D. C. B., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37283-2 · Cited by 68
GDSCTools for mining pharmacogenomic interactions in cancer
Cokelaer, T., Chen, E. D., Iorio, F., Menden, M. P., Lightfoot, H. W., Sáez-Rodríguez, J., & Garnett, M. J. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx744 · Cited by 67
Self-citationQi, Y., Lu, M., Wang, Y., Tang, Z., Gao, Z., Tian, J., Xu, F., Li, Y., & Liu, J. (2019) · Organic Chemistry Frontiers · doi:10.1039/c9qo00634f · Cited by 67
Kovar, H. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.947963 · Cited by 68
Organoid development in cancer genome discovery
Gao, D., & Chen, Y. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.02.007 · Cited by 71
Optimal Drug Prediction From Personal Genomics Profiles
Sheng, J., Li, F., & Wong, S. T. C. (2015) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2015.2412522 · Cited by 67
Engert, F., Schneider, C., Weiβ, L. M., Probst, M., & Fulda, S. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0587 · Cited by 67
Teicher, B. A., Polley, E. C., Kunkel, M. W., Evans, D., Silvers, T. R., Delosh, R., Laudeman, J. A., Ogle, C., Reinhart, R. A., Selby, M. J. P., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0074 · Cited by 68
Adolescent and Young Adult (AYA) Oncology in the United States
Shaw, P. H., Reed, D. R., Yeager, N. D., Zebrack, B., Castellino, S. M., & Bleyer, A. (2015) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000318 · Cited by 66
Zhang, K., Myllymäki, S.-M., Gao, P. H., Devarajan, R., Kytölä, V., Nykter, M., Wei, G., & Manninen, A. (2017) · Oncogene · doi:10.1038/onc.2017.177 · Cited by 65
Comparison and validation of genomic predictors for anticancer drug sensitivity
Papillon‐Cavanagh, S., Jay, N. D., El-Hachem, N., Olsen, C., Bontempi, G., Aerts, H. J. W. L., Quackenbush, J. F., & Haibe‐Kains, B. (2013) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2012-001442 · Cited by 65
Sharifi-Noghabi, H., Jahangiri, S., Smirnov, P., Hon, C. S.-Y., Mammoliti, A., Nair, S. K., Mer, A. S., Ester, M., & Haibe‐Kains, B. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab294 · Cited by 66
In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies
Rosa, R., Monteleone, F., Zambrano, N., & Bianco, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113209990226 · Cited by 67
E3 Ubiquitin Ligase HOIP Attenuates Apoptotic Cell Death Induced by Cisplatin
MacKay, C., Carroll, E., Ibrahim, A. F. M., Garg, A. K., Inman, G. J., Hay, R. T., & Alpi, A. F. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2131 · Cited by 65
Hirt, C., Papadimitropoulos, A., Muraro, M. G., Mele, V., Panopoulos, E., Cremonesi, E., Ivánek, R., Schultz‐Thater, E., Droeser, R. A., Mengus, C., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.05.037 · Cited by 69
Moran, D. M., Trusk, P. B., Pry, K., Paz, K., Sidransky, D., & Bacus, S. S. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0649 · Cited by 64
Round cell sarcomas – Biologically important refinements in subclassification
Mariño‐Enríquez, A., & Fletcher, C. D. �. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.04.022 · Cited by 65
Gonçalves, E., Behan, F. M., Louzada, S., Arnol, D., Stronach, E. A., Yang, F., Yusa, K., Stegle, O., Iorio, F., & Garnett, M. J. (2019) · Genome biology · doi:10.1186/s13059-019-1637-z · Cited by 60
Self-citationQuantitative Proteome Landscape of the NCI-60 Cancer Cell Lines
Guo, T., Luna, A., Rajapakse, V. N., Koh, C. C., Wu, Z., Liu, W., Sun, Y., Gao, H., Menden, M. P., Xu, C., et al. (2019) · iScience · doi:10.1016/j.isci.2019.10.059 · Cited by 63
Self-citationRoth, B. J., Krilov, L., Adams, S., Aghajanian, C. A., Bach, P. B., Braiteh, F., Brose, M. S., Ellis, L. M., Erba, H. P., George, D. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1938 · Cited by 63
Stepwise-edited, human melanoma models reveal mutations’ effect on tumor and microenvironment
Hodis, E., Triglia, E. T., Kwon, J., Biancalani, T., Zakka, L. R., Parkar, S., Hütter, J.-C., Buffoni, L., Delorey, T. M., Phillips, D., et al. (2022) · Science · doi:10.1126/science.abi8175 · Cited by 61
Single cell resolution in vivo imaging of DNA damage following PARP inhibition
Yang, K. S., Köhler, R. H., Landon, M., Giedt, R. J., & Weissleder, R. (2015) · Scientific Reports · doi:10.1038/srep10129 · Cited by 61
Molecular Pathways: Targeting ETS Gene Fusions in Cancer
Feng, F. Y.-C., Brenner, J. C., Hussain, M., & Chinnaiyan, A. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0275 · Cited by 63
Cheeseman, M. D., Chessum, N. E. A., Rye, C. S., Pasqua, E., Tucker, M. J., Wilding, B., Evans, L. E., Lepri, S., Richards, M., Sharp, S. Y., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01055 · Cited by 63
Gene isoforms as expression-based biomarkers predictive of drug response in vitro
Safikhani, Z., Smirnov, P., Thu, K. L., Silvester, J., El-Hachem, N., Quevedo, R., Lupien, M., Mak, T. W., Cescon, D. W., & Haibe‐Kains, B. (2017) · Nature Communications · doi:10.1038/s41467-017-01153-8 · Cited by 60
Janizek, J. D., Dincer, A. B., Çelik, S., Chen, H., Chen, W., Naxerova, K., & Lee, S. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01034-0 · Cited by 66
Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells
Goard, C. A., Chan‐Seng‐Yue, M., Mullen, P., Quiroga, A. D., Wasylishen, A. R., Clendening, J. W., Sendorek, D. H. S., Haider, S. A., Lehner, R. S., Boutros, P. C., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2800-y · Cited by 62
Fadlullah, M. Z. H., Chiang, I. K., Dionne, K. R., Yee, P. S., Gan, C. P., Sam, K. K., Tiong, K. H., Ng, K. W., Martı́n, D., Lim, K. P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8533 · Cited by 62
Advances in Small-Cell Lung Cancer (SCLC) Translational ResearchPreprint
Drapkin, B. J., & Rudin, C. M. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a038240 · Cited by 63
Roelants, C., Pillet, C., Franquet, Q., Sarrazin, C., Peilleron, N., Giacosa, S., Guyon, L., Fontanell, A., Fiard, G., Long, J., et al. (2020) · Cancers · doi:10.3390/cancers12010232 · Cited by 66
Durinikova, E., Buzo, K., & Arena, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01981-z · Cited by 61
Base editing screens define the genetic landscape of cancer drug resistance mechanisms
Coelho, M. A., Strauß, M. E., Watterson, A., Cooper, S., Bhosle, S. G., Illuzzi, G., Karakoç, E., Dinçer, C., Vieira, S. F., Sharma, M., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01948-8 · Cited by 65
Self-citationSingh, D. P., Kour, P., Banerjee, T., & Swain, D. (2025) · Archives of Computational Methods in Engineering · doi:10.1007/s11831-025-10255-2 · Cited by 61
The value of monitoring to control evolving populations
Fischer, A., Vázquez-Garćıa, I., & Mustonen, V. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409403112 · Cited by 63
Targeting the LKB1 Tumor Suppressor
Zhao, R., & Xu, Z. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106095811 · Cited by 64
Beglyarova, N., Banina, E., Zhou, Y., Mukhamadeeva, R., Andrianov, G. V., Bobrov, E., Lysenko, E., Skobeleva, N., Gabitova, L., Restifo, D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0149 · Cited by 62
Insights from animal models of bladder cancer: recent advances, challenges, and opportunities
John, B. A., & Said, N. A. (2017) · Oncotarget · doi:10.18632/oncotarget.17714 · Cited by 61
Chen, J., Peng, H., Han, G., Cai, H., & Cai, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty662 · Cited by 61
Puig-Butille, J. A., Vinyals, A., Ferreres, J. R., Aguilera, P., Cabré, E., Tell-Martí, G., Marcoval, J., Mateo, F., Palomero, L., Badenas, C., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.01.021 · Cited by 58
Workman, P., Al‐Lazikani, B., & Clarke, P. A. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.06.004 · Cited by 60
Wirth, M., Stojanovic, N., Christian, J. G., Paul, M. C., Stauber, R. H., Schmid, R. M., Häcker, G. A., Krämer, O. H., Saur, D., & Schneider, G. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku763 · Cited by 62
Silvers, C. R., Liu, Y.-R., Wu, C.-H., Miyamoto, H., Messing, E. M., & Lee, Y.-F. (2016) · Oncotarget · doi:10.18632/oncotarget.8024 · Cited by 60
McGrail, D. J., Lin, C. C.-J., Garnett, J., Liu, Q., Mo, W., Dai, H., Lu, Y., Yu, Q., Ju, Z., Yin, J., et al. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0011-6 · Cited by 59
Self-citationPharmacoproteomic characterisation of human colon and rectal cancer
Frejno, M., Chiozzi, R. Z., Wilhelm, M., Koch, H., Zheng, R., Klaeger, S., Ruprecht, B., Meng, C., Kramer, K., Jarząb, A., et al. (2017) · Molecular Systems Biology · doi:10.15252/msb.20177701 · Cited by 61
Tumor organoids: From inception to future in cancer research
Yang, L., Yang, S., Li, X., Li, B., Li, Y., Zhang, X., Ma, Y., Peng, X., Jin, H., Fan, Q., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.005 · Cited by 62
Patient-derived organoids of non-small cells lung cancer and their application for drug screening
Li, Y., Gao, Y., Liang, B., Cao, X., Sun, Z., Yu, J. H., Liu, Z. D., & Han, Y. (2020) · Neoplasma · doi:10.4149/neo_2020_190417n346 · Cited by 61
Falgreen, S., Dybkær, K., Young, K. H., Xu-Monette, Z. Y., El‐Galaly, T. C., Laursen, M. B., Bødker, J. S., Kjeldsen, M. K., Schmitz, A., Nyegaard, M., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1237-6 · Cited by 59
PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma
Jiang, T., Pan, Y., Wan, Z., Lin, Y., Zhu, B., Yuan, Z.-G., Ma, Y., Shi, Y., Zeng, T., Dong, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay0152 · Cited by 60
Wang, Y., Velho, S., Vakiani, E., Peng, S., Bass, A. J., Chu, G. C., Gierut, J. J., Bugni, J. M., Der, C. J., Philips, M. R., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0198 · Cited by 59
Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox
Yang, J., Milasta, S., Hu, D., AlTahan, A. M., Interiano, R. B., Zhou, J., Davidson, J. T., Low, J. A., Lin, W., Bao, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0826 · Cited by 59
Hao, D., Li, J., Jia, S., Meng, Y., Zhang, C., Wang, L., & Di, L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0638 · Cited by 59
Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts
Mer, A. S., Ba-Alawi, W., Smirnov, P., Wang, Y. X., Brew, B., Ortmann, J., Tsao, M., Cescon, D. W., Goldenberg, A., & Haibe‐Kains, B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0349 · Cited by 57
Metadata
- Authors
- Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., Liu, Q., Iorio, F., Surdez, D., Chen, L., Milano, R. J., Bignell, G. R., Tam, A. T., Davies, H., Stevenson, J. A., Barthorpe, S., Lutz, S. R., Kogera, F., Lawrence, K., McLaren-Douglas, A., Mitropoulos, X., Mironenko, T., Thi, H., Richardson, L., Zhou, W., Jewitt, F., Zhang, T., O’Brien, P., Boisvert, J. L., Price, S., Hur, W., Yang, W., Deng, X., Butler, A., Choi, H. G., Chang, J. W., Baselga, J., Stamenkovic, I., Engelman, J. A., Sharma, S. V., Delattre, O., Saez-Rodriguez, J., Gray, N. S., Settleman, J., Futreal, P. A., Haber, D. A., Stratton, M. R., Ramaswamy, S., McDermott, U., & Benes, C. H.
- Affiliations
- Wellcome Sanger Institute (GB)
- Harvard University (US)
- European Bioinformatics Institute (GB)
- Institut Curie (FR)
- Centre Hospitalier Universitaire Vaudois (CH)
- Howard Hughes Medical Institute (US)
- Corresponding author
- McDermott, Ultan
- Benes, Cyril H.
- ORCID
- Garnett, Mathew J.
- Greenman, Chris D.
- Dastur, Anahita
- Lau, King Wai
- Greninger, Patricia
- Thompson, I. Richard
- Luo, Xi
- Liu, Qingsong
- Iorio, Francesco
- Surdez, Didier
- Chen, Li
- Davies, Helen
- Barthorpe, Syd
- Lawrence, Karl
- Mironenko, Tatiana
- Richardson, Laura
- Zhou, Wenjun
- Zhang, Tinghu
- O’Brien, Patrick
- Hur, Wooyoung
- Yang, Wanjuan
- Deng, Xianming
- Choi, Hwan Geun
- Chang, Jae Won
- Baselga, Jose
- Stamenkovic, Ivan
- Engelman, Jeffrey A.
- Delattre, Olivier
- Gray, Nathanael S.
- Settleman, Jeffrey
- Futreal, P. Andrew
- Haber, Daniel A.
- Stratton, Michael R.
- McDermott, Ultan
- Benes, Cyril H.
- Venue
- Nature
- Published
- 2012-03
- Volume
- 483
- Issue
- 7391
- Pages
- 570-575
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3349233
- OpenAlex
- W2125789330
- Cited by
- 2,456
- References
- 39
- Citations by year
- 2026: 106 · 2025: 101 · 2024: 114 · 2023: 145 · 2022: 161 · 2021: 228 · 2020: 162 · 2019: 183 · 2018: 212 · 2017: 198 · 2016: 214 · 2015: 199 · 2014: 197 · 2013: 153 · 2012: 82
- FWCI
- 66.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- SERVAL (Université de Lausanne) (acceptedVersion, other-oa)
- IRIS (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Wellcome Trust (086357)
- Cancer Research UK
- National Institutes of Health (5u54hg006097-03)
- National Human Genome Research Institute (1U54HG006097-01, U54-HG006097)
- National Institute of General Medical Sciences (P41GM079575)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- drug sensitivity, drug resistance, pharmacogenomics, cancer cell lines, genomic biomarkers, oncogene addiction, Ewing sarcoma, PARP inhibitors, topoisomerase inhibitors, SLFN11, tissue-specific biomarkers
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Cell Survival, Drug Screening Assays, Antitumor, Genetic Markers, Humans, Indoles, Neoplasms, Pharmacogenetics, Phthalazines, Piperazines, Sarcoma, Ewing, Oncogene Proteins, Fusion, Genome, Human, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Genomics, RNA-Binding Protein EWS, Cell Line, Tumor, Proto-Oncogene Protein c-fli-1, Genes, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
